Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352652 | 0.84 | HTT (0.53) | TAS1R3TAS1R1TAS1R2CYP1A2CYP3A4 | |
| SCHEMBL29554593 | 0.83 | MAPT (0.52) | TAS1R3TAS1R1TAS1R2CYP1A2CYP3A4 | |
| SCHEMBL312135 | 0.83 | MAPT (0.52) | TAS1R3TAS1R1TAS1R2CYP1A2CYP3A4 | |
| SCHEMBL4546533 | 0.83 | HPGD (0.53) | CYP3A4TSHRALDH1A1GAAMAPT | |
| SCHEMBL703101 | 0.83 | TSHR (0.65) | TAS1R3TAS1R1TAS1R2CYP1A2TSHR | |
| SCHEMBL40769 | 0.82 | SMN1; SMN2 (0.55) | TAS1R3TAS1R1ALDH1A1MAPTMEN1 | |
| SCHEMBL30475402 | 0.82 | SMN1; SMN2 (0.55) | TAS1R3TAS1R1ALDH1A1MAPTMEN1 | |
| SCHEMBL11025910 | 0.81 | TAS1R3 (0.50) | TAS1R3TAS1R1TAS1R2CYP1A2CYP3A4 | |
| Hydrogen Sulfide SCHEMBL28759691 | 0.81 | TSHR (0.63) | TAS1R3TAS1R1TAS1R2CYP1A2TSHR | |
| SCHEMBL14894712 | 0.81 | TAS1R3 (0.50) | TAS1R3TAS1R1TAS1R2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| US-11464783-B2 | Heterocyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3980406-A1 | HETEROCYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20200397797-A1 | HETEROCYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2020247504-A1 | HETEROCYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-8822233-B2 | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | GIRI BRIJ PAL (US) | 2014-09-02 | — | — | US | disclosed |
| US-8772327-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8546150-B2 | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | Michigan Diagnostics, L.L.C. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-5466687-A | Anticholesterol agents | DR. KARL THOMAE GMBH (DE) | 1995-11-14 | — | — | US | disclosed |
| US-5455273-A | Antiacholesterol agents | KARL THOMAE GMBH (DE) | 1995-10-03 | — | — | US | disclosed |
| EP-0596326-B1 | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | THOMAE GMBH DR K (DE) | 1995-08-23 | — | — | EP | disclosed |
| CN-1093082-A | N, two substituted aryl Cycloalkyl amines of N-and salt thereof, contain the pharmaceutical composition of this compound and use with and preparation method thereof | THOMAE GMBH DR K (DE) | 1994-10-05 | — | — | CN | disclosed |
| CN-1090849-A | Arylidene-1-azacycloparaffin and aralkyl-1-azacycloparaffin, their salt contains medicament and the application and their preparation process of these compounds | THOMAE GMBH DR K (DE) | 1994-08-17 | — | — | CN | disclosed |
| EP-0599203-A1 | N,N-disubstituted arylcycloacrylamines, their salts, medicines containing these compounds and their use as well as processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1994-06-01 | — | — | EP | disclosed |
| EP-0596326-A1 | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | Dr. Karl Thomae GmbH (DE) | 1994-05-11 | — | — | EP | disclosed |
| EP-0126225-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TRIALKYLSILYLOXYMALONIC-ACID DINITRILES | BAYER AG (DE) | 1986-11-26 | — | — | EP | disclosed |
| US-4620022-A | REACTING TRIALKYLSILYL CYANIDE WITH ACID HALIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1986-10-28 | — | — | US | disclosed |
| EP-0126225-A1 | Process for the preparation of substituted trialkylsilyloxymalonic-acid dinitriles | BAYER AG (DE) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464783-B2 | Heterocyclic compounds | SLC10A1, CFTR, PKD1 | TAS1R3 3902/4885TAS1R1 3358/4885TAS1R2 3809/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | TAS1R3 4737/4885TAS1R1 4804/4885TAS1R2 4784/4885 |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | TAS1R3 4527/4885TAS1R1 4486/4885TAS1R2 4530/4885 |
| US-20200397797-A1 | HETEROCYCLIC COMPOUNDS | SLC10A1, CFTR, PKD1 | TAS1R3 3902/4885TAS1R1 3358/4885TAS1R2 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.